PLOD1 and obesity due to melanocortin 4 receptor deficiency: Prescriptions based on BZYQ can significantly reduce the serum luteinizing hormone (LH), testosterone (T), fasting blood glucose (FBG), and fasting insulin (FINS) levels and the homeostatic model assessment for insulin resistance (HOMA-IR) and improve the ovarian function and pregnancy rate in patients with obesity suffering from PCOS with SPSD [13, 14].